| Why has model‐informed precision dosing not yet become common clinical reality? Lessons from the past and a roadmap for the future AS Darwich, K Ogungbenro, AA Vinks, JR Powell, JL Reny, N Marsousi, ... Clinical Pharmacology & Therapeutics 101 (5), 646-656, 2017 | 238 | 2017 |
| Meta-analysis of the turnover of intestinal epithelia in preclinical animal species and humans AS Darwich, U Aslam, DM Ashcroft, A Rostami-Hodjegan Drug Metabolism and Disposition 42 (12), 2016-2022, 2014 | 233 | 2014 |
| Interplay of metabolism and transport in determining oral drug absorption and gut wall metabolism: a simulation assessment using the “Advanced Dissolution, Absorption … A S. Darwich, S Neuhoff, M Jamei, A Rostami-Hodjegan Current drug metabolism 11 (9), 716-729, 2010 | 214 | 2010 |
| Model-informed precision dosing: background, requirements, validation, implementation, and forward trajectory of individualizing drug therapy AS Darwich, TM Polasek, JK Aronson, K Ogungbenro, DFB Wright, ... Annual review of pharmacology and toxicology 61 (1), 225-245, 2021 | 142 | 2021 |
| The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery MJ Brill, A van Rongen, EP van Dongen, B van Ramshorst, EJ Hazebroek, ... Pharmaceutical research 32, 3927-3936, 2015 | 77 | 2015 |
| A mechanistic pharmacokinetic model to assess modified oral drug bioavailability post bariatric surgery in morbidly obese patients: interplay between CYP3A gut wall metabolism … AS Darwich, D Pade, BJ Ammori, M Jamei, DM Ashcroft, ... Journal of Pharmacy and Pharmacology 64 (7), 1008-1024, 2012 | 73 | 2012 |
| IMI–Oral biopharmaceutics tools project–Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results A Margolskee, AS Darwich, X Pepin, L Aarons, A Galetin, ... European Journal of Pharmaceutical Sciences 96, 610-625, 2017 | 70 | 2017 |
| Trends in oral drug bioavailability following bariatric surgery: examining the variable extent of impact on exposure of different drug classes AS Darwich, K Henderson, A Burgin, N Ward, J Whittam, BJ Ammori, ... British journal of clinical pharmacology 74 (5), 774-787, 2012 | 70 | 2012 |
| Virtual bioequivalence for achlorhydric subjects: The use of PBPK modelling to assess the formulation-dependent effect of achlorhydria K Doki, AS Darwich, N Patel, A Rostami-Hodjegan European journal of pharmaceutical sciences 109, 111-120, 2017 | 58 | 2017 |
| IMI–Oral biopharmaceutics tools project–Evaluation of bottom-up PBPK prediction success part 3: Identifying gaps in system parameters by analysing In Silico performance across … AS Darwich, A Margolskee, X Pepin, L Aarons, A Galetin, ... European Journal of Pharmaceutical Sciences 96, 626-642, 2017 | 50 | 2017 |
| Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1‐OH‐midazolam in morbidly obese and weight loss surgery patients MJE Brill, PAJ Välitalo, AS Darwich, B van Ramshorst, HPA Van Dongen, ... CPT: pharmacometrics & systems pharmacology 5 (1), 20-30, 2016 | 50 | 2016 |
| time to revisit Child‐Pugh score as the basis for predicting drug clearance in hepatic impairment E El‐Khateeb, AS Darwich, B Achour, V Athwal, A Rostami‐Hodjegan Alimentary Pharmacology & Therapeutics 54 (4), 388-401, 2021 | 47 | 2021 |
| What does it take to make model-informed precision dosing common practice? Report from the 1st Asian symposium on precision dosing TM Polasek, A Rostami-Hodjegan, DS Yim, M Jamei, H Lee, H Kimko, ... The AAPS journal 21, 1-9, 2019 | 45 | 2019 |
| IMI–oral biopharmaceutics tools project–evaluation of bottom-up PBPK prediction success part 1: Characterisation of the OrBiTo database of compounds A Margolskee, AS Darwich, X Pepin, SM Pathak, MB Bolger, L Aarons, ... European Journal of Pharmaceutical Sciences 96, 598-609, 2017 | 44 | 2017 |
| Deconvolution and IVIVC: exploring the role of rate-limiting conditions A Margolskee, AS Darwich, A Galetin, A Rostami-Hodjegan, L Aarons The AAPS journal 18, 321-332, 2016 | 42 | 2016 |
| Drug disposition and modelling before and after gastric bypass: immediate and controlled‐release metoprolol formulations I Gesquiere, AS Darwich, B Van der Schueren, J de Hoon, M Lannoo, ... British journal of clinical pharmacology 80 (5), 1021-1030, 2015 | 40 | 2015 |
| Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically … A Olivares-Morales, Y Kamiyama, AS Darwich, L Aarons, ... European Journal of Pharmaceutical Sciences 67, 32-44, 2015 | 39 | 2015 |
| Role of pharmacokinetic modeling and simulation in precision dosing of anticancer drugs AS Darwich, K Ogungbenro, OJ Hatley, A Rostami-Hodjegan Translational Cancer Research 6 (Suppl 10), 2017 | 37 | 2017 |
| Evaluation of an In Silico PBPK Post‐Bariatric Surgery Model through Simulating Oral Drug Bioavailability of Atorvastatin and Cyclosporine AS Darwich, D Pade, K Rowland‐Yeo, M Jamei, A Åsberg, H Christensen, ... CPT: pharmacometrics & systems pharmacology 2 (6), 1-9, 2013 | 36 | 2013 |
| Forecasting oral absorption across biopharmaceutics classification system classes with physiologically based pharmacokinetic models S Hansmann, A Darwich, A Margolskee, L Aarons, J Dressman Journal of Pharmacy and Pharmacology 68 (12), 1501-1515, 2016 | 34 | 2016 |
Masoud JameiCertara UKAdresse e-mail validée de ieee.org